Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
56 hedge funds and large institutions have $541M invested in Akcea Therapeutics Inc in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 9 closing their positions.
32% more call options, than puts
Call options by funds: $3.19M | Put options by funds: $2.42M
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
3% more capital invested
Capital invested by funds: $526M → $541M (+$14.9M)
2% less funds holding
Funds holding: 57 → 56 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$58.4M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$7.89M |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
+$2.94M |
| 4 |
BlackRock
New York
|
+$2.89M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$2.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.6M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.48M |
| 3 |
PA
Perceptive Advisors
New York
|
-$2.49M |
| 4 |
Jane Street
New York
|
-$524K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$386K |
AKCA Hedge Fund Activity: Q2 2018 in Review
56 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q2 2018, worth a combined $541M — up 2.8% from $526M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AKCA and 8 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 23 added.
The largest buyer was Fidelity Investments, adding an estimated $58.4M. The largest seller was Wellington Management Group, cutting an estimated $18.6M.
- 56 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q2 2018, down from 57 in Q1 2018.
- Funds reported $541M of Akcea Therapeutics Inc stock for Q2 2018, up 2.8% quarter-over-quarter.
- 8 funds opened new Akcea Therapeutics Inc positions in Q2 2018 and 9 closed out, a net change of -1 holder.
- The largest Akcea Therapeutics Inc buyer in Q2 2018 was Fidelity Investments, an estimated $58.4M added.
- The largest Akcea Therapeutics Inc seller in Q2 2018 was Wellington Management Group, an estimated $18.6M sold.
Based on aggregated 13F filings for Q2 2018.